NDAORALFOR SUSPENSION
Approved
Jun 2013
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9m ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEGERID OTC is an oral suspension combining omeprazole (a proton pump inhibitor) with sodium bicarbonate for rapid acid neutralization. It is indicated for frequent heartburn and acid reflux in over-the-counter settings. The sodium bicarbonate component accelerates omeprazole onset compared to standard formulations.
Peak
Product is in peak maturity with moderate competitive pressure (30/100), suggesting stable team requirements and focus on market defense rather than growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZEGERID OTC offers career opportunities in mature product management, OTC commercial strategy, and consumer brand building. Roles emphasize market defense, cost management, and consumer marketing expertise rather than clinical or innovation-focused work.
Brand Manager (OTC)Consumer Marketing Manager
Worked on ZEGERID OTC at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.